NASDAQ:XTLB XTL Biopharmaceuticals Q4 2025 Earnings Results & Report $1.88 -0.09 (-4.79%) As of 03:50 PM Eastern This is a fair market value price provided by Massive. Learn more. XTL Biopharmaceuticals reported Q4 2025 earnings on June 30, 2026. The company reported EPS of -$0.10, while revenue was ($0.26) million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateJune 30, 2026TimeAfter Market Closes XTL Biopharmaceuticals EPS ResultsActual EPS-$0.10Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AXTL Biopharmaceuticals Revenue ResultsActual Revenue($0.26) millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile XTL Biopharmaceuticals Q4 2025 Earnings FAQ Did XTL Biopharmaceuticals beat earnings estimates for Q4 2025? XTL Biopharmaceuticals (NASDAQ:XTLB) reported earnings of -$0.10 per share for Q4 2025. The report was announced on Tuesday, June 30, 2026. What was XTL Biopharmaceuticals' revenue for Q4 2025? XTL Biopharmaceuticals reported revenue of ($0.26) million for Q4 2025. XTL Biopharmaceuticals Earnings HeadlinesXTL Biopharmaceuticals Ltd. Sponsored ADRJuly 8, 2026 | cnn.comXTL Biopharmaceuticals Ltd. American Depositary Shares (XTLB) After-HoursJuly 1, 2026 | nasdaq.comElon pays this company. Every time.Every Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Starlink dish and AI satellite Elon launches. When Nvidia tried to buy the company, Elon reportedly fought the deal. Now his filing for 1,000,000 satellites could expand its revenue stream sharply. Dylan believes the stock could see significant movement starting October 24th.October 14 at 1:00 AM | Behind the Markets (Ad)XTL Biopharmaceuticals Completes Acquisition of Psyga Bio to Establish Psychedelic Biotechnology PlatformJune 30, 2026 | quiverquant.comQXTL Completed the Acquisition of Psyga Bio Ltd.June 30, 2026 | globenewswire.comXTL Biopharmaceuticals Adjourns Extraordinary Shareholder Meeting to June 29, 2026June 23, 2026 | tipranks.comSee More XTL Biopharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like XTL Biopharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XTL Biopharmaceuticals and other key companies, straight to your email. Email Address About XTL BiopharmaceuticalsXTL Biopharmaceuticals (NASDAQ:XTLB) is an Israel-based clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases and other conditions with significant unmet medical needs. The company’s research activities have historically centered on therapies intended to modulate the immune system. XTL has pursued drug candidates for diseases including systemic lupus erythematosus and lupus nephritis, as well as other immune-related disorders. Its development programs have included antibody-based and other targeted therapies designed to address the underlying biological mechanisms of autoimmune disease. The company is headquartered in Israel and conducts its activities through research, development and clinical-stage programs rather than through a broad portfolio of marketed medicines. Information about its pipeline and corporate strategy may change as development programs advance.View XTL Biopharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
